摘要
背景与目的:新辅助化疗已成为治疗局部晚期乳腺癌的主要手段之一,随机试验证明新辅助化疗与术后辅助化疗同样有效,并且能提高保乳率。本文旨在观察多西他赛联合卡培他滨在局部晚期乳腺癌新辅化疗应用中的近期疗效及不良反应。方法:52例局部晚期乳腺癌患者,接受多西他赛75mg/m2静脉滴注,第1天;卡培他滨2000mg/m2,分2次口服,第1～14天。21d为1个周期。治疗3～4个周期后评价疗效及不良反应。结果:新辅助化疗临床疗效总有效率(CR+PR)为80.7%,其中3例(5.8%)为病理完全缓解。主要不良反应是粒细胞减少、脱发和手足综合征等。结论:多西他赛联合卡培他滨治疗局部晚期乳腺癌疗效显著,不良反应可耐受,是局部晚期乳腺癌新辅助化疗的有效方案。
Background and purpose： Neoadjuvant chemotherapy has become a major therapeutic strategy for the treatment of locally advanced breast cancer. Randomized trials comparing this approach to adjuvant chemotherapy have demonstrated that neoadjuvant chemotherapy was as efficacious as adjuvant chemotherapy and allowed for a higher rate of breast conservation. This study was to evaluate the efficacy and toxicity of docetaxel plus capecitabine in the neoadjuvant chemotherapy of locally advanced breast cancer （LABC）. Methods： Fifty-two patients with LABC were treated with docetaxel 75 mg/m^2, dl; Capecitabine 2 000 mg/m2, d1-14. The chemotherapy was repeated every 3 weeks. Efficacy and toxicities were reviewed after 3 to 4 cycles of chemotherapy. Results： The CR＋PR rate was 80.7%. A pathological complete response in the breast was achieved in 5.8% of patients after 4 cycles of docetaxel/capecitabine. The adverse reactions were neutropenia, alopecia and hand-foot syndrome. Conclusion： The combination ofdocetaxel and capecitabine was well tolerated and effective in LABC for neoadjuvant chemotherapy.
出处
《中国癌症杂志》
CAS
CSCD
北大核心
2009年第11期861-863,共3页
China Oncology
关键词
乳腺癌
新辅助化疗
多西他赛
卡培他滨
breast cancer
neoadjuvant chemotherapy
docetaxel
capecitabine
